Ceftazidime

Summary

Ceftazidime (CHEMBL44354) is an approved small-molecule antibacterial drug (ATC J01DD02); indicated across 14 conditions including urinary tract infection and pyelonephritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DD02
• Indications: 14 conditions
• Clinical trials: 41
• Chemistry: 546.6 Da · C22H22N6O7S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL44354
Name	Ceftazidime
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5481173
ChEBI	CHEBI:3508
ATC	J01DD02
Molecular formula	C22H22N6O7S2
Molecular weight	546.6
InChIKey	ORFOPKXBNMVMKC-DWVKKRMSSA-N

SMILES: CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]

IUPAC name: (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

ChEBI definition: A third-generation cephalosporin antibiotic bearing pyridinium-1-ylmethyl and {[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.

Pharmacological roles (ChEBI): antibacterial drug, EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor, drug allergen.

Also known as: Ceftazidima, Ceftazidime, Ceftazidime anhydrous, Ceftazidime component of avycaz, Ceftazidime component of zavicefta, Ceftazidime hydrate, Ceftazidime pentahydrate, Ceptaz, Ceftazidime (arginine formulation), Fortaz, Fortam, Fortum

Parent form; salt/anhydrous children: CHEMBL1200768, CHEMBL3186392

Patent coverage: 9,865 distinct patent families (34,650 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Estrogen receptor, Progesterone receptor, Peroxisome proliferator-activated receptor gamma, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	6.75	AC50	180	nM	CHEMBL_ACT_25187904
NR1I2	6.49	AC50	325	nM	CHEMBL_ACT_25223629
PPARG	6.42	AC50	380	nM	CHEMBL_ACT_25113861
PGR	5.64	AC50	2300	nM	CHEMBL_ACT_25221859

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

14 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	4	MONDO:0100338	EFO:0003103
pyelonephritis	4	MONDO:0006939	EFO:1001141
pneumonia	4	MONDO:0005249	EFO:0003106
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
infectious peritonitis	4	MONDO:0004522	EFO:0008588
parametritis	4	MONDO:0006887	EFO:1001084
skin disorder	3	MONDO:0005093	EFO:0000701
staphylococcal infection	3	MONDO:0024313	EFO:1001849
bacterial meningitis	2	MONDO:0006670	EFO:1000831
cystic fibrosis	1	MONDO:0009061	MONDO:0009061
osteomyelitis	0	MONDO:0005246	EFO:0003102

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 41.

Phase distribution

Phase	Trials
Not specified	15
PHASE4	10
PHASE2	8
PHASE1	5
PHASE2/PHASE3	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07016165	PHASE4	RECRUITING	Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT00173901	PHASE4	UNKNOWN	Adverse Drug Reactions of Different Brands of Ceftazidime Injection
NCT00333385	PHASE4	TERMINATED	Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
NCT01044719	PHASE4	UNKNOWN	Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
NCT01784445	PHASE4	COMPLETED	Post ERCP Pancreatitis Prevention in Average Risk Patients
NCT02463747	PHASE4	UNKNOWN	Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia
NCT02504827	PHASE4	COMPLETED	Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis
NCT04187755	PHASE4	COMPLETED	Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever
NCT04948463	PHASE4	COMPLETED	Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
NCT05977868	PHASE4	TERMINATED	Comparing Oral Versus Parenteral Antimicrobial Therapy
NCT01455246	PHASE2/PHASE3	TERMINATED	Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
NCT02837835	PHASE3	COMPLETED	Lung Concentrations of Ceftazidime in Patients With Ventilator-associated Pneumonia
NCT03404739	PHASE2/PHASE3	UNKNOWN	Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia
NCT06406114	PHASE2	RECRUITING	Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT00690378	PHASE2	COMPLETED	Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
NCT00752219	PHASE2	COMPLETED	Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
NCT00752882	PHASE2	UNKNOWN	Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration
NCT00786305	PHASE2	COMPLETED	Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
NCT00921024	PHASE2	COMPLETED	Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections
NCT02475733	PHASE2	COMPLETED	Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).
NCT02497781	PHASE2	COMPLETED	Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)
NCT00823238	PHASE1	COMPLETED	Comparison of Antibiotics for Pseudomonas in Early CF
NCT01290900	PHASE1	COMPLETED	A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
NCT01430910	PHASE1	COMPLETED	A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately
NCT02822950	PHASE1	COMPLETED	A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients
NCT03376529	PHASE1	COMPLETED	Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741
NCT06210542	Not specified	NOT_YET_RECRUITING	Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
NCT06864585	Not specified	NOT_YET_RECRUITING	A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
NCT07085624	Not specified	NOT_YET_RECRUITING	Early Optimization of Ceftazidime Regimen in Critical Care
NCT00195923	Not specified	COMPLETED	Prospective Randomized Evaluation of Antibiotic Regimen Following Appendectomy for Perforated Appendicitis
NCT00435305	Not specified	TERMINATED	Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion
NCT00579956	Not specified	UNKNOWN	A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis
NCT01344512	Not specified	COMPLETED	Population Pharmacokinetics of Anti-infectious Drugs in Children
NCT01785641	Not specified	COMPLETED	Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients
NCT02526004	Not specified	COMPLETED	Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
NCT02787057	Not specified	COMPLETED	Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
NCT02840136	Not specified	TERMINATED	LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients
NCT03754387	Not specified	UNKNOWN	Antibiotic Therapy vs Laparscopic Appendectomy in Pediatric Chronic Appendicitis
NCT04319328	Not specified	COMPLETED	Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
NCT04402359	Not specified	COMPLETED	Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).